| FORM 3 | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
| |||||||||||||||
1. Name and Address of Reporting Person*
(Street)
| 2. Date of Event Requiring Statement (Month/Day/Year) 10/15/2020 | 3. Issuer Name and Ticker or Trading Symbol Kiromic Biopharma, Inc. [ KRBP ] | |||||||||||||
| 4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
| 5. If Amendment, Date of Original Filed (Month/Day/Year) | ||||||||||||||
6. Individual or Joint/Group Filing (Check Applicable Line)
| |||||||||||||||
| Table I - Non-Derivative Securities Beneficially Owned | |||
|---|---|---|---|
| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
| Common Stock | 402,000 | D | |
| Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||
|---|---|---|---|---|---|---|---|
| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) | ||
| Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
| Stock Options | (1) | 11/09/2027 | Common Stock | 8,587 | 6.64 | D | |
| Stock Options | (2) | 03/13/2028 | Common Stock | 57,241 | 11.88 | D | |
| Restricted Stock Units | (3) | 08/20/2030 | Common Stock | 21,112 | 0 | D | |
| Restricted Stock Units | (4) | 08/20/2030 | Common Stock | 186,135 | 0 | D | |
| Explanation of Responses: |
| 1. Fully vested. |
| 2. 25% of stock options vested on the one year anniversary of the vesting start date (December 15, 2018), 25% of stock options vested on December 15, 2019, 25% of the stock options will vest on December 15, 2020 and 25% of the stock options will vest on December 15, 2021. |
| 3. 25% of the Restricted Stock Units vest at the end of each of four consecutive calendar quarters, beginning on June 30, 2020. Notwithstanding anything to the contrary contained in in the RSU Agreement, to the extent that the Grantee is subject to a lock up or similar agreement at the time of the vesting of any RSUs granted, then the vesting date of such RSUs shall be deferred until such time as such lock up or similar agreement has expired. |
| 4. The Restricted Stock Units vest upon achievement of certain corporate milestones which were approved by the Company's Board of Directors on August 20, 2020. Notwithstanding anything to the contrary contained in in the RSU Agreement, to the extent that the Grantee is subject to a lock up or similar agreement at the time of the vesting of any RSUs granted, then the vesting date of such RSUs shall be deferred until such time as such lock up or similar agreement has expired. |
| /s/ Tony Tontat | 10/16/2020 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 5 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||
